mergers & acquisitions
Syncona Taking Freeline Therapeutics Private; Providing $15M in Financing
The additional funds will allow the company to continue to study its gene therapy in Gaucher disease and GBA1-linked Parkinson's disease.
Merck Acquiring Caraway Therapeutics for Precision Neurodegenerative, Rare Disease Drugs
In the deal valued at $610 million, Caraway will be able to leverage Merck's R&D resources to advance its early-stage therapies.
Aranscia Acquires Select Assets of PGx Firm YouScript From Invitae
Diagnostics software and services company Aranscia purchased select assets of YouScript from Invitae for an undisclosed amount.
Selecta Biosciences, Cartesian Therapeutics Merge to Create Public RNA Cell Therapy Firm
The combined company, which will operate under the name of the previously private firm Cartesian Therapeutics, will trade on the Nasdaq as "RNAC."
European Commission Approves Pfizer Acquisition of Seagen
Once the deal closes later this year or early next year, Pfizer will gain the HER2-targeted agent Tukysa and about a dozen other Seagen oncology assets.